Compartmental models for apical efflux by p-glycoprotein - Part 1: Evaluation of model complexity

Pharmaceutical Research

Volumn 31, Issue 2, 2014, Pages 347-359

  Nagar, Swati ^a   Tucker, Jalia ^a   Weiskircher, Erica A ^b   Bhoopathy, Siddhartha ^b   Hidalgo, Ismael J ^b   Korzekwa, Ken ^a  

^a TEMPLE UNIVERSITY   (United States)

^b Absorption Systems   (United States)

Author keywords

compartmental models; intracellular concentrations; kinetics; P glycoprotein; transporters

Indexed keywords

CYCLOSPORIN; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL TRANSPORT; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EXPOSURE; MDCK CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; DOGS; HUMANS; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE TRANSPORT PROTEINS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS;

EID: 84896720758     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1164-7     Document Type: Article

References (45)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215-36.
2. Chu X, Korzekwa K, Elsby R, Fenner K, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94:126-141.
3. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929-39.
4. Yabe Y, Galetin A, Houston JB. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos. 2011;39(10):1808-14.
5. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in the hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45-78.
6. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39(3):353-62.
7. Guideline on the Investigation of Drug Interactions EMA Guidline: www.ema.europa.eu
8. Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. FDA Guidance for Industry: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ default.htm
9. Korzekwa KR, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos. 2012;40(5):865-76.
10. Zamek-Gliszczynski MJ, Lee CA, Poirier A., Bentz J, et al. ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans. Clin Pharmacol Ther. 2013;94:64-79.
11. Ménochet K, Kenworthy KE, Houston JB, Galetin A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther. 2012;341(1):2-15.
12. Kalvass JC, Pollack GM. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res. 2007;24(2):265-76.
13. Agnani D, Acharya P, Martinez E, Tran TT, Abraham F, Tobin F, et al. Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm. PLoS One. 2011;6(10):e25086.
14. Sun H, Pang KS. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab Dispos. 2008;36(1):102-23.
15. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr opinion Genet Dev. Elsevier; 1996;6(5):610-617.
16. Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature Engl. 2012;490(7421):566-9.
17. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Intracellular Compartments and Protein Sorting. In Molecular Biology of the Cell. 4th ed. NY: Garland Science; 2002.
18. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos. 2002;30(12):1497-503.
19. Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, et al. Application and limitation of inhibitors in drug-transporter interactions studies. Int J Pharm. 2008;356(1-2):12-8.
20. Nagar S, Korzekwa K. Commentary: nonspecific protein binding versus membrane partitioning: It is not just Semantics. Drug Metab Dispos. 2012;40(9):1649-52.
21. Butor C, Davoust J. Apical to basolateral surface area ratio and polarity of MDCK cells grown on different supports. Exp Cell Res. 1992;203(1):115-27.
22. Corradini MG, Peleg M. Estimating non-isothermal bacterial growth in foods from isothermal experimental data. J Appl Microbiol. 2005;99(1):187-200.
23. Sahin S, Estudante M, Benet L. Role of P-gp on the Transport of Verapamil Across MDCK and MDR1-MDCK Cell Monolayers. AAPS Journal 9, poster T3474 (2007).
24. Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, Löscher W. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol. 2010;160(6):1453-63.
25. Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. Drug Metab Dispos. 2008;36(2):452-60.
26. Schlager SI, Ohanian SH. Tumor cell lipid composition and sensitivity to humoral immune killing. II. Influence of plasma membrane and intracellular lipid and fatty acid content. J Immunol. 1980;125(2):508-17.
27. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985;26(9):1015-35.
28. Carpenter HM, Hedstrom OR, Siddens LK, Duimstra JR, Cai ZW, Fisher KA, et al. Ultrastructural, protein, and lipid changes in liver associated with chlordecone treatment of mice. Fundam Appl Toxicol. 1996;34(1):157-64.
29. Janmey PA, Kinnunen PK. Biophysical properties of lipids and dynamic membranes. Trends Cell Biol. 2006;16(10):538-46.
30. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos. 2010;38(2):215-22.
31. Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, et al. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos. 2010;38(1):168-76.
32. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol. 1998;124(7):1413-8.
33. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579-88.
34. Kalvass JC, Graff CL, Pollack GM. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice. Pharm Res. 2004;21(10):1867-70.
35. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97(11):2517-24.
36. Fujino H, Yamada I, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase-effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice. Drug Metab Pharmacokinet Japan; 2002;17(5):449-56.
37. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96(4):1698-705.
38. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst. 1996;88(14):994-9.
39. Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, Dasenbrock J, et al. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol. 1999;127(1):43-50.
40. Salama NN, Kelly EJ, Bui T, Ho RJ. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci. 2005;94(6):1216-25.
41. Geyer J, Gavrilova O, Petzinger E. Brain penetration of ivermectin and selamectin in mdr1a, b P-glycoprotein- and bcrp- deficient knockout mice. J Vet Pharmacol Ther. 2009;32(1):87-96.
42. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther. 2004;310(2):648-55.
43. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res. 1999;16(8):1213-8.
44. Leusch A, Volz A, Müller G, Wagner A, Sauer A, Greischel A, et al. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci. 2002;16(3):119-28.
45. Desrayaud S, De Lange EC, Lemaire M, Bruelisauer A, De Boer AG, Breimer DD. Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice. J Pharmacol Exp Ther. 1998;285(2):438-43.